Fig. 3

Reduction in T cell ex vivo reactivity following GAT107 treatment. Proliferation of lymphocytes from placebo- and GAT107-treated mice was assessed based on [3H] thymidine incorporation in the presence of MOG_35–55 (a) or in the presence of ConA, anti-CD3 antibody, or LPS (b). IL-17, IFN-γ, IL-6, and IL-10 levels following MOG_35–55 stimulation were measured by ELISA, and the results are expressed as percentage of the mean secretion ± SE value of the placebo-treated group based on data from three separate experiments (c) (n = 6 for each group). The expression of immune cell surface markers was assessed by FACS, as described in the “Methods” (d). Following GAT107 treatment, a significant decrease in the expression of CD11b (macrophages), CD11c (dendritic cells), and CCR5-positive cells was observed, but there was no significant change in the number of CD4-, CD8-, and MHC class II-expressing cells (n = 3) (*p < 0.05, **p < 0.001)